Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study

Cardiovascular Revascularization Medicine

Volumn 13, Issue 2, 2012, Pages 95-100

  Natarajan, Madhu K ^a   Strauss, Bradley H ^b,f   Rokoss, Michael ^a   Buller, Christopher E ^b,c   Mancini, John G B ^c   Xie, Changchun ^d   Sheth, Tej N ^a   Goodhart, David ^e   Cohen, Eric A ^f   Seidelin, Peter ^g   Harper, William ^a   Gerstein, Hertzel C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e FOOTHILLS HOSPITAL   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Coronary disease; Diabetes mellitus; Insulin; Restenosis; Stents

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; ISOPHANE INSULIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; EVENING DOSAGE; FEMALE; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; BLOOD GLUCOSE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84859627510     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2011.12.001     Document Type: Article

References (44)

1. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998, 32:584-589.
2. Berry C, Tardif JC, Bourassa MG Coronary heart disease in patients with diabetes. J Am Coll Cardiol 2007, 49(6):643-656.
3. Aronson D, Bloomgarden Z, Rayfield EJ Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996, 27(3):528-535.
4. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997, 95(6):1366-1369.
5. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998, 32(7):1866-1873.
6. Van Belle E, Abolmaali K, Bauters C, et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999, 34(2):476-485.
7. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004, 109(19):2273-2278.
8. Maisel WH Unanswered questions - drug-eluting stents and the risk of late thrombosis. N Engl J Med 2006, 356(10):981-984.
9. Iijima R, Ndrepepa G, Mehilli J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007, 154:688-693.
10. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients. Circulation 2004, 109:1366-1370.
11. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
12. Stone KE, Chiquette E, Chilton RJ Diabetic endovascular disease: role of coronary artery revascularization. Am J Cardiol 2007, 99(4A):105B-112B.
13. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004, 43:8-14.
14. Corpus RA, O'Neill WW, Dixon SR, et al. Relation of hemoglobin A1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol 2003, 92:1282-1292.
15. Kornowski R, Fuchs S Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2004, 43(1):15-17.
16. Mazeika P, Prasad N, Bui S, Seidelin PH Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003, 145(6):1013-1021.
17. Lindsay J, Sharma AK, Canos D, Nandalur M, Pinnow E, Apple S, et al. Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C. Cardiovasc Revasc Med 2007, 8:15-20.
18. Breen DM, Dhaliwall JK, Chan KK, Guo J, Lam L, Bendeck MP, et al. Insulin inhibits and oral sucrose increases neointimal growth after arterial injury in rats. J Vasc Res 2010, 47:412-422.
19. Breen DM, Chan KK, Dhaliwall JK, Ward MR, Al Koudsi N, Lam L, et al. Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler Thromb Vasc Biol 2009, 29:1060-1066.
20. Kim T, Chan KK, Dhaliwall JK, Huynh N, Suen R, Uchino H, et al. Anti-atherogenic effect of insulin in vivo. J Vasc Res 2005, 42:455-462.
21. Murthy SN, Sukhanov S, McGee J, Greco JA, Chandra S, Delafontaine P, et al. Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Mol Cell Biochem 2009, 330(1-2):1-8.
22. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996, 94(6):1247-1254.
23. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654-2660.
24. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112(18):2792-2798.
25. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006, 29(1):101-106.
26. Katayama T, Ueba H, Tsuboi K, et al. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 2007, 153(5):e1-e7.
27. Rosmarakis ES, Falagas ME Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 2007, 154:144-150.
28. Nicholls SJ, Sipahi I, Schoenhagen P, et al. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. Am Heart J 2006, 152:67-74.
29. Nissen SE, Tuzcu EM, Schenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004, 291:1071-1080.
30. Mancini GB, Simon SB, McGillem MJ, et al. Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. Circulation 1987, 75:452-460.
31. Mancini GB, Yeoh E, Kamimura C, et al. A comparison of quantitative coronary angiography systems using a unique set of in vivo coronary stenosis images. Can J Cardiol 2001, 17(7):785-791.
32. Smith SC, Faxon D, Cascio W, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group VI: revascularization in diabetic patients. Circulation 2002, 105:165-169.
33. Legrand V Therapy insight: diabetes and drug-eluting stents. Nat Clin Pract Cardiovasc Med 2007, 4(3):143-150.
34. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999, 99(5):633-640.
35. Abizaid A, Costa MA, Centemero M, et al. Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001, 104(5):533-538.
36. Kubota T, Kubota N, Moroi M, Terauchi Y, Kobayashi T, Kamata K, et al. Lack of insulin receptor substrate- 2 causes progressive neointima formation in response to vessel injury. Circulation 2003, 107:3073-3080.
37. Natarajan R, Gonzales N, Xu L, Nadler JL Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem Biophys Res Commun 1992, 187(1):552-560.
38. Patel NA, Chalfant CE, Yamamoto M, Watson JE, Eichler DC, Cooper DR Acute hyperglycemia regulates transcription and posttranscriptional stability of PKCbetaII mRNA in vascular smooth muscle cells. FASEB J 1999, 13(1):103-113.
39. Sodhi CP, Kanwar YS, Sahai A Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 2003, 284(3):H846-H852.
40. Seki N, Hashimoto N, Sano H, Horiuchi S, Yagui K, Makino H, et al. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism 2003, 52(12):1558-1563.
41. Sun J, Xu Y, Dai Z, Sun Y Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol Cell Endocrinol 2009, 313(1-2):64-69.
42. Nilsson-Berglund LM, Zetterqvist AV, Nilsson-Ohman J, Sigvardsson M, Gonzalez Bosc LV, Smith ML, et al. Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia. Arterioscler Thromb Vasc Biol 2010, 30(2):218-224.
43. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119:351-357.
44. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. The BARI 2D Study Group. N Engl J Med 2009, 360(24):2503-2515.